Clobazam oral suspension barcode error flagged in Class 4 defect notice
- Sponsor
- Martindale Pharmaceuticals Ltd
- Drug
- clobazam
MHRA issued a Class 4 medicines defect notification for Martindale clobazam oral suspension batches carrying an incorrect linear barcode; no recall is required.
What this means
Clobazam is a long-acting benzodiazepine used in the UK and elsewhere to help control certain seizure disorders and (in some jurisdictions) as a short-term anti-anxiety medication. Martindale Pharmaceuticals sells the oral suspension formulation used in dispensing pharmacies. MHRA has issued a Class 4 medicines defect notification — the lowest severity level, meaning no product recall is required and no risk to product quality — because three specific batches of Martindale's Clobazam 5 mg/5 mL and 10 mg/5 mL oral suspension were packaged in cartons carrying the wrong linear barcode. The barcode printed on the cartons is the one for the branded version (Tapclob) rather than for the generic product. The 2D barcode used for authentication and traceability is correct, and pharmacies are advised to rely on the 2D barcode for identification while stock cycles through. Patients do not need to take any action; the medicine inside is unaffected.
From the source
Class 4 Medicines Defect Notification: Martindale Pharmaceuticals Ltd, Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150ml, EL(26)A/38
Martindale Pharmaceuticals has informed the MHRA of an error with the linear barcode of some batches of Clobazam 5mg/5mL and 10mg/5mL Oral Suspension 150mL.
From: Medicines and Healthcare products Regulatory Agency
Published: 17 September 2026
Message type: Medicines recall/notification
Medical specialty: Dispensing GP practices and Pharmacy
Issued: 17 September 2026
DMRC reference number
DMRC- 40754020
Marketing Authorisation Holder
Martindale Pharmaceuticals Ltd
Medicine Details
Clobazam Martindale Pharma 5 mg/5 mL Oral Suspension 150ml
PL: 00156/0322
Active ingredient: clobazam
SNOMED code: 42289011000001100
GTIN: 5014124144224
Affected Lot Batch Numbers
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 0162858 | 05/2028 | 1 | 18/08/2026 |
| 0163605 | 07/2028 | 1 | 14/09/2026 |
Medicine Details
Clobazam Martindale Pharma 10 mg/5 mL Oral Suspension 150ml
PL: 00156/0323
Active ingredient: clobazam
SNOMED code: 42289711000001100
GTIN: 5014124144231
Affected Lot Batch Numbers
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 0163858 | 07/2028 | 1 | 14/09/2026 |
Background
Martindale Pharmaceuticals has informed the MHRA of an error with the linear barcode of some batches of Clobazam 5mg/5mL and 10mg/5mL Oral Suspension 150mL.
The above batches were packaged in cartons containing an incorrect pre-printed linear barcode. The linear barcode present represents the GTIN for the branded version of the product (Tapclob). It should instead reflect the generic name: Clobazam. The code in the 2D printed barcode is correct.
Example for 5mg/5mL 150mL pack:
The associated strength and bottle size documented on the pre-printed package remain correct and unchanged.
Full batch quantities:
Batch 0162858: 5,544 units
Batch 0163605: 2,277 units
Batch 0163858: 4,631 units
Future batches of Clobazam for both strengths and pack size will have the barcode corrected via the application of a sticker until new cartons are available to maintain supply for patients.
Advice for Healthcare Professionals:
There is no risk to product quality as a result of this issue, therefore the affected batches are not being recalled.
Healthcare professionals are advised to note the above-mentioned batches of Clobazam Oral Suspension and use the serialized 2D barcode for authentication and traceability, as it remains accurate. The linear barcode on the carton should not be used for product identification.
Additional precautions should be considered by wholesalers and pharmacies using the linear barcode in a wholesale facility.
Advice for Patients:
This notification relates to a barcode error on the outer packaging of the product. The medicine itself is not affected, and patients do not need to take any action.
Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information:
For further information, medical enquiries and stock information, contact: Licensed@ethypharm.com
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk
Download document
Class 4 Medicines Defect Notification: Martindale Pharmaceuticals Ltd, Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150ml, EL(26)A/38
Updates to this page
Published 17 September 2026
Contents
Reproduced from MHRA News · view original · public domain or open-licensed government work
Drug Watch — recent news on clobazam
- Alert: Martindale clobazam oral suspension 150mL - Dispensing Doctors' Association
- MHRA Issues Class 4 Defect Notification for Martindale Clobazam Oral Suspension - Wansom AI
- Epilepsy Rescue Drug Study: AIIMS Study Finds Oral Clobazam Stops Long Focal Seizures In About A Minute - ABP Live English
- Clobazam Stock – 3 July 2026 - Epilepsy Action
- On-chain finance: On-chain IPOs and on-chain ICOs, a new frontier in the trillion-dollar market - 链捕手ChainCatcher